Back to search
FDAFDA · Food and drugs·Recall number Z-0506-2018

Peripheral Diamondback 1.50 Solid OAD, a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy.

Published February 14, 2018 · Recall initiated: September 14, 2017

Summary

FDA records medical device Class II recall Z-0506-2018, published February 14, 2018 and initiated September 14, 2017. Recalling firm: Cardiovascular Systems Inc; Status: Terminated; Reported quantity: 8; Lot: Lot # 190217 Part #: 7-10011 Model # DBP-150SOLID145. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cardiovascular Systems, Inc. (CSI) is removing the products because it was identified that the labeling for two lots of product s were potentially inadvertently switched during production.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cardiovascular Systems Inc
Distributor
FL, IL, MI, MN, MO, NY, SC, TX, and WI
Lot
Lot # 190217 Part #: 7-10011 Model # DBP-150SOLID145
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Peripheral Diamondback 1.50 Solid OAD, a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and who are acceptable candidates for percutaneous transluminal atherectomy. recalled?

Yes. FDA published recall Z-0506-2018 on February 14, 2018. Reported hazard: Cardiovascular Systems, Inc. (CSI) is removing the products because it was identified that the labeling for two lots of product s were potentially inadvertently switched during production.

What should I do if I have this product?

Voluntary: Firm initiated · Letter